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Somatostatin (SST) and cortistatin (CORT) regulate numerous endocrine secretions and their absence 
[knockout (KO)-models] causes important endocrine-metabolic alterations, including pituitary 
dysregulations. We have demonstrated that the metabolic phenotype of single or combined SST/CORT 
KO-models is not drastically altered under normal conditions. However, the biological actions of SST/
CORT are conditioned by the metabolic-status (e.g. obesity). Therefore, we used male/female SST- 
and CORT-KO mice fed low-fat (LF) or high-fat (HF) diet to explore the interplay between SST/CORT 
and obesity in the control of relevant pituitary-axes and whole-body metabolism. Our results showed 
that the SST/CORT role in the control of GH/prolactin secretions is maintained under LF- and HF-diet 
conditions as SST-KOs presented higher GH/prolactin-levels, while CORT-KOs displayed higher GH- and 
lower prolactin-levels than controls under both diets. Moreover, the impact of lack of SST/CORT on 
the metabolic-function was gender- and diet-dependent. Particularly, SST-KOs were more sensitive to 
HF-diet, exhibiting altered growth and body-composition (fat/lean percentage) and impaired glucose/
insulin-metabolism, especially in males. Conversely, only males CORT-KO under LF-diet conditions 
exhibited significant alterations, displaying higher glucose-levels and insulin-resistance. Altogether, 
these data demonstrate a tight interplay between SST/CORT-axis and the metabolic status in the 
control of endocrine/metabolic functions and unveil a clear dissociation of SST/CORT roles.
Somatostatin (SST) and cortistatin (CORT) are two closely related neuropeptides that share high structural, phar-
macological and functional similarities1,2. SST3 is a pleiotropic neuropeptide widely distributed throughout the 
organism, which regulates a plethora of physiological functions, including inhibition of basal and stimulated 
secretion from endocrine and exocrine cells, inhibition of gastrointestinal motility, modulation of neurotransmis-
sion, metabolism and immune function, as well as inhibition of cell proliferation and differentiation1,3–6. In con-
trast, CORT7 is mainly produced in the cerebral cortex and was originally identified for its role in the modulation 
of sleep cycles, neuronal activity and immune system7–11. Subsequently, CORT was suggested as an endocrine/
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metabolic sibling of SST; however, recent evidence demonstrated that CORT is able to trigger unique, and even 
opposite, endocrine and non-endocrine actions from those exerted by SST, including the regulation of endocrine 
secretions, the control of immune response or the modulation of neuronal activity2,9,12–20. These functional differ-
ences may have various causes, such as minor amino acid sequence disparities between SST and CORT, dissimilar 
capacity to bind and/or activate common receptors (sst1–5)1 or, to the ability of CORT, but not SST, to bind other 
non-sst receptors (i.e. ghrelin receptor, GHSR1a, or mas-related G protein coupled receptor MrgX2)21,22.
SST and CORT play complex regulatory roles within the endocrine-metabolic milieu. Indeed, SST and CORT 
are crucial regulators of several metabolic hormones such as growth hormone (GH), prolactin or ACTH/costi-
costerone, and have also been shown to suppress insulin secretion in vitro2,23, strongly suggesting a relevant role 
in the modulation of whole-body metabolic function. Accordingly, previous studies using genetically engineered 
preclinical mouse models have shown that lack of endogenous SST or CORT drastically, but distinctly, alters the 
normal hormone secretion patterns. Indeed, SST-knockout (KO) mice exhibit gender-dependent elevated levels 
of GH, prolactin and ACTH/corticosterone, while CORT-KO mice also present gender-dependent elevated levels 
of GH and ACTH/corticosterone but reduced levels of prolactin13,24–27. In addition, although male and female 
SST-KO mice exhibit comparable glucose/insulin sensitivity to WT controls13,28, male CORT-KO mice present a 
clear insulin resistance under chow-diet, normal weight conditions13, confirming the gender-dependent role of 
SST/CORT on metabolic function. However, SST and CORT actions might also be dependent on, or influenced 
by specific endocrine/metabolic conditions, like obesity13,24–27, which may suggest that the final biological actions 
of SST and CORT may be conditioned by the specific metabolic status. Therefore, the present study has been 
conceived to unveil, for the first time, the putative interplay between SST or CORT and an extreme metabolic situ-
ation such as diet-induced obesity in the control of the most relevant pituitary hormonal axes and the whole-body 
metabolic function by using male and female SST- and CORT-KO mice fed a low-fat or a high-fat diet and, their 
respective lean and obese littermate controls.
Results
SST and CORT exerted gender- and diet-dependent effects on BW. To unveil the putative inter-
play between SST or CORT and obesity, we firstly analyzed BW gain and body composition in male and female 
SST-KO, CORT-KO and their littermate WT-controls fed a LF- or a HF-diet. Under LF-conditions, SST-KO 
females exhibited significantly higher BW gain (p = 0.006, two-way ANOVA), while male SST-KO or CORT-KO 
males and females did not show significant differences with WT-controls (Fig. 1A,B). As expected, HF-feeding 
significantly increased BW gain in all experimental groups (p < 0.05, two-way ANOVA) (Fig. 1A,B). Under 
HF-diet conditions, male SST-KO exhibited increased BW gain compared to controls (Fig. 1B), while female 
SST-KO and CORT-KO male and female did not show differences (Fig. 1A,B).
The increase in BW observed in SST-KO mice, especially in males, was not associated to increased calo-
ries intake. Indeed, although HF-fed animals exhibited reduced food intake compared to genotype- and 
gender-matched LF-fed mice, SST-KO and CORT-KO mice exhibited similar food intake than their controls 
within the same diet (Fig. 1C).
The predominant effect of SST in the control of BW gain was further supported by the BWs at sacrifice 
(Fig. 2A). Specifically, HF-diet induced significant BW increases in all the experimental groups compared to 
LF-fed counterparts (p < 0.001, two-way ANOVA) (Fig. 2A). However, only SST-KO mice exhibited significant 
difference on BW compared to WT-controls (p = 0.012 and p = 0.005 two-way ANOVA in females and males, 
respectively), being significantly marked in HF-fed males (p < 0.05, Bonferroni test; Fig. 2A). No significant 
changes were observed in CORT-KO mice compared to WT-controls (Fig. 2A).
SST and CORT exerted gender- and diet-dependent effects on body composition. HF-diet 
feeding increased visceral and subcutaneous fat depots weight in most of the experimental groups compared to 
LF-diet controls (p < 0.001, two-way ANOVA within genotype and gender; Fig. 2B,C). Indeed, circulating leptin 
levels were elevated in all the HF-diet fed groups compared to LF-fed mice (p < 0.05, two-way ANOVA within 
genotype and gender; Supplemental Fig. 2A). However, only lack of endogenous SST elicited significant changes 
in fat depot weight (Fig. 2B,C), exhibiting a significant increment on visceral and subcutaneous fat depots weight 
irrespective of gender (p < 0.001, two-way ANOVA), while lack of CORT did not exert any significant effect. 
These changes were mostly observed in SST-KO males (Fig. 2B,C) and were particularly pronounced in the sub-
cutaneous adipose depot of HF-diet fed SST-KO males (1.8-fold; p < 0.001, Bonferroni test).
Similarly, liver weights were altered by the absence of SST but not CORT. Indeed, SST-KO females and males 
exhibited increased liver weights (p < 0.001 and p = 0.025, two-way ANOVA, respectively), being more pro-
nounced in females, irrespective of the diet, and in LF-diet males (Fig. 2D). In contrast, no significant changes in 
pancreas weight were found in any experimental groups (Supplemental Fig. 2B).
Lack of SST and CORT altered the production and secretion of pituitary hormones. We ana-
lyzed the interaction of diet-induced obesity with the lack of SST and CORT on the production and secretion of 
key pituitary hormones by determining GH, IGF and PRL levels at sacrifice (Fig. 3). GH is a pivotal metabolic 
hormone secreted in a pulsatile fashion and alterations in GH secretion pattern are difficult to identify by simple 
point bleeding. However, our measurements demonstrated a significant effect of the genotype on GH levels of 
SST-KO females and males (p = 0.001 and p = 0.05, two-way ANOVA, respectively), being especially significant 
in SST-KO females (p < 0.001 and p < 0.05, Bonferroni test in LF- and HF-fed, respectively; Fig. 3A). However, 
these changes cannot be explained by increased expression of pituitary GH mRNA (Supplemental Fig. 3A), which 
suggests the existence of alternative mechanism in SST-KO mice. In contrast, and likely due to the reasons men-
tioned above, only significant increases in GH levels were found in LF-fed CORT-KO males compared with 
controls (Fig. 3A); while differences in other CORT-KO mice groups were not apparent. Similarly, no changes 
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Figure 1. Growth rate and food intake of male and female, LF- and HF-fed, SST-KO, CORT-KO and 
control mice. Female (A) and male (B) SST-KO, CORT-KO and control (WT) mice were fed a LF- of a HF-diet 
starting at 4 weeks of age and body weights were recorder weekly until sacrifice (14–16 weeks of diet). Statistical 
differences were assessed by two-way ANOVA within genotype and gender followed by Bonferroni post-hoc 
test within each time point [significant differences are indicated by *(WT-LF vs. WT-HF) or #(KO-LF vs. 
KO-HF)]. (C) Food intake was estimated at 15–17 weeks of age (11–13 weeks of diet) by daily weighting food 
provided and withdrawn during 7 consecutive days. Statistical differences were assessed by two-way ANOVA 
within genotype and gender followed by Bonferroni post-hoc test [significant differences between LF- and HF-
fed mice are indicated by asterisks (***p < 0.001; **p < 0.01; *p < 0.05). Data represent MEM ± SEM of n = 6–12 
mice per gender, diet and genotype.
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Figure 2. Body, visceral and subcutaneous fat depots and liver weights of male and female, LF- and HF-fed, 
SST-KO, CORT-KO and control mice. Body (A), visceral (B) and subcutaneous (C) fat depots and liver (D) 
weights of female and male SST-KO, CORT-KO and control (WT) mice fed a LF- of a HF-diet were recorder at 
sacrifice (14–16 weeks of diet). Statistical differences were assessed by two-way ANOVA within genotype and 
gender (indicated below each graph) followed by Bonferroni post-hoc test [significant differences between LF- 
and HF-fed or between WT and KO mice are indicated by asterisks (***p< 0.001; **p < 0.01; *p < 0.05)]. Data 
represent MEM ± SEM of n = 6–12 mice per gender, diet and genotype.
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in pituitary GH mRNA levels in CORT-KO mice were found (Supplemental Fig. 3A). Remarkably, changes in 
GH levels could not be explained by alterations in the expression of hypothalamic factors (GHRH or ghrelin, 
Figure 3. GH, IGF-I and prolactin (PRL) levels of male and female, LF- and HF-fed, SST-KO, CORT-KO 
and control mice. GH (A), IGF-I (B) and PRL (C) levels of female and male SST-KO, CORT-KO and control 
(WT) mice fed a LF- of a HF-diet determined at sacrifice (14–16 weeks of diet). Statistical differences were 
assessed by two-way ANOVA within genotype and gender (indicated below each graph) followed by Bonferroni 
post-hoc test [significant differences between LF- and HF-fed or between WT and KO mice are indicated by 
asterisks (***p < 0.001; **p < 0.01; *p < 0.05)]. Data represent MEM ± SEM of n = 6–12 mice per gender, diet 
and genotype.
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Supplemental Fig. 3C,D); however, since we analyzed the expression levels of the whole hypothalamus, local 
changes in specific hypothalamic nuclei cannot be discarded.
Furthermore, although no significant changes were found in CORT-KOs compared to controls 
(Supplemental Fig. 4B,C), SST-KO mice showed drastic alterations in the hepatic expression of MUP-3 and 
PRL-R, two reliable markers of altered GH pulsatile pattern. Particularly, female LF-fed SST-KO mice presented 
higher levels of PRL-R, while female HF-fed SST-KO mice showed reduced levels of MUP-3 expression compared 
to diet-matched controls (Supplemental Fig. 4B,C), suggesting altered GH secretion patterns. The most striking 
results were obtained in SST-KO males, which exhibited significantly elevated levels of PRL-R and reduced levels 
of MUP-3 compared to controls (Supplemental Fig. 4B,C), indicating a drastically feminized GH pattern.
Similarly, HF-feeding seemed to induce a significant elevation in IGF-I levels in SST-KO and CORT-KO mice 
(p < 0.001, two-way ANOVA), which was specially pronounced in controls (Fig. 3B). Although CORT-KO mice 
exhibited similar IGF-I levels than controls, SST-KO male mice showed reduced IGF-I levels, irrespective of 
the diet (p = 0.001, two-way ANOVA; Fig. 3B). Interestingly, the circulating pattern of IGF-I was similar to the 
hepatic expression pattern of IGF-I in SST-KO mice, although no significant differences were detected in this 
cohort (Supplemental Fig. 4A). No changes were observed in the hepatic expression of IGF-I of CORT-KO mice.
Inasmuch as we have previously reported different roles of SST and CORT in the control of PRL levels13, 
we sought to determine the putative interaction between SST or CORT and diet-induced obesity in PRL. 
Consistently, SST-KO mice exhibited similar PRL level elevations under both dietary conditions (Fig. 3C), being 
especially drastic in females (p = 0.001, two-way ANOVA) irrespective of diet (Fig. 3C). In addition, PRL lev-
els were significantly reduced in CORT-KO mice (effect of genotype: p < 0.001, two-way ANOVA), being these 
changes especially marked in HF-diet mice (p < 0.001 and p < 0.05, Bonferroni test in HF-fed females and males, 
respectively) compared to the gender-matched controls (Fig. 3C). In both cases, changes in circulating PRL levels 
were not clearly associated to altered pituitary PRL expression of SST-KO and CORT-KO mice, except in the case 
of female SST-KO wherein PRL expression at the pituitary levels were increased in LF-fed SST-KO and HF-fed 
controls compared to LF-fed controls (Supplemental Fig. 3B).
SST and CORT exerted gender- and diet-dependent effects on glucose/insulin homeostasis. 
To explore the role of SST and CORT in the interaction between diet and glucose/insulin homeostasis, SST-KO 
and CORT-KO mice were subjected to in vivo dynamic insulin/glucose sensitivity tests. HF-diet feeding induced 
a drastic, significant impairment of glucose clearance during the GTT, which was observed in all the experi-
mental groups (Fig. 4). Of note, lack of CORT did not impact glucose clearance. On the other hand, although 
female SST-KO mice exhibited similar GTT curves than WT-controls, male SST-KO mice fed a HF-diet showed 
impaired glucose clearance compared to controls (Fig. 4), while these differences were not observed in LF-fed 
mice. These results were further confirmed by the analysis of the area under the curves (AUC) calculated from 
the GTTs, which showed a significant effect of the diet (p < 0.001, two-way ANOVA) and of genotype in SST-KO 
males (p = 0.049, two-way ANOVA) (Supplemental Fig. 5). These altered GTT curves were accompanied by 
changes in fasting, but not fed, glucose levels in SST-KO males (Supplemental Figure 6A). Of note, no alterations 
in fed glucose were observed in SST-KO and CORT-KO groups (Supplemental Figure 6B). Similarly, fed insulin 
levels were altered in SST-KO males (p = 0.012, two-way ANOVA), being significantly elevated in SST-KO HF-fed 
males compared to HF-fed controls and LF-fed SST-KO mice; while no alterations were observed in other exper-
imental groups (Supplemental Figure 6C).
Implementation of ITTs served to confirm a certain degree of insulin resistance of HF-fed WT males but not 
females, mainly indicated by a lower recovery of glucose levels at 120 minutes post-injection (Fig. 5). Interestingly, 
LF-fed CORT-KO males were more insulin resistant than LF-fed WT-controls (Fig. 5); while no differences where 
observed in other experimental groups.
Discussion
SST and CORT are two neuropeptides widely known by their ability to regulate numerous endocrine secretions, 
particularly those from the pituitary gland (GH or PRL) and the gastrointestinal tract (pancreatic and gut secre-
tions)2. Indeed, although they exert different, even opposite effects in the regulation of several non-endocrine 
functions, both peptides seem to similarly regulate endocrine secretions2, with the only reported exception of 
PRL13. The fact that both peptides exhibit a marked inhibitory action on GH release and other endocrine secre-
tions suggests that lack of SST or CORT would cause profound alterations in relevant endocrine/metabolic pro-
cesses. However, genetically engineered animal models have revealed that, under normal conditions, the single 
or combined deletion of SST and/or CORT does not drastically influence the metabolic phenotypic of these 
animals13,29,30. Indeed, despite the fact that SST and CORT are two primary inhibitors of GH secretion by acting 
through their canonical receptors (sst1–5)13,26,31,32 and, that SST-KO or CORT-KO mice display markedly ele-
vated plasma GH levels13,25, SST-KO and CORT-KO mice do not exhibit a correspondingly enhanced somatic 
growth13,25 or major changes in body mass, IGF plasma levels or glucose/insulin metabolism13,24,25,29,30,32.
However, SST and CORT actions are clearly dependent on, and influenced by, the endocrine/metabolic situ-
ation, such as fasting25,27 and/or obesity13,24–27,33, which suggest that the final biological actions of SST and CORT 
may be conditioned by the specific metabolic status. For this reason, in this study, we used male and female 
SST- and CORT-KO mice fed a LF or a HF diet to thoroughly explore, for first time, the interplay between SST or 
CORT and obesity in the control of the most relevant pituitary hormonal axes and whole-body metabolic func-
tion (the main results are summarized in Table 1) and found striking differences that may help to shed light to the 
role of endogenous SST and CORT in the control of the endocrine/metabolic milieu under extreme metabolic 
conditions.
As expected, SST-KO and CORT-KO mice exhibited drastic deregulations in key pituitary axes, such as 
GH and PRL, which were overtly maintained under LF- and HF-conditions. In particular, male and female 
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SST-KO and CORT-KO mice showed elevated plasmatic GH levels irrespective of the diet (except for the case 
of CORT-KO females), which is consistent with previous reports observing similar changes under normal and 
extreme metabolic conditions13,25,27,29,34,35. Of note, these changes seemed to be more pronounced under LF con-
ditions, wherein SST-KO and CORT-KO mice exhibited obvious elevated GH levels compared to controls. The 
fact that these changes were less evident under HF-feeding could be associated to the fact that obesity represents 
an extreme metabolic status that courses with clear impairments in GH pulses36,37, which could be masking the 
loss of SST/CORT inhibitory effect. Remarkably, these changes in plasma GH levels were not accompanied by 
parallel alterations in the expression of pituitary GH mRNA, which is consistent with previous reports25,27,29,38,39 
and reinforces the idea that SST and CORT could be exerting regulatory roles at different levels of the regulatory 
axis of the GH secretion, including the hypothalamic level, the control of secretory pulses or the regulation of 
other hormonal systems (ghrelin, glucocorticoids, etc.) as previously suggested13,25,27,29,30,33. Nevertheless, it is 
important to highlight that, despite the difficulty of assessing GH levels due to its pulsatile secretion pattern, the 
results presented herein serve to confirm previous results on the crucial role of endogenous SST and CORT on the 
control of GH secretion and to expand them to different dietary patterns. Indeed, the analysis of the expression of 
GH pattern-sensitive genes in the liver of SST-KO under LF- and HF-conditions further reinforced the idea that 
Figure 4. Dynamic glucose tolerance test on male and female, LF- and HF-fed, SST-KO, CORT-KO and 
control mice. Glucose tolerance tests (GTTs) were performed at 16–18 weeks of age (12–14 weeks of diet) after 
an overnight fast (2 g/kg glucose, ip) on female and male SST-KO, CORT-KO and control (WT) mice. Statistical 
differences were assessed by two-way ANOVA within genotype and gender followed by Bonferroni post-hoc 
test within each time point [significant differences are indicated by *(WT-LF vs. WT-HF), #(KO-LF vs. KO-HF) 
or $(WT-HF vs. KO-HF)]. Data represent MEM ± SEM of n = 6–12 mice per gender, diet and genotype.
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the GH secretion pattern is dramatically altered by the lack of SST inasmuch as SST-KO male mice exhibited a 
feminized hepatic expression of PRLR and MUP3 gene [two genes whose expression depends on the GH pulsatile 
pattern40], which is clearly maintained under LF- and HF-feeding, consistent with previous data on male SST-KO 
fed a chow diet25.
Similarly, the effect of SST and CORT on the secretion of PRL was not influenced by the metabolic status 
since SST-KO mice presented elevated and CORT-KO exhibited reduced PRL levels, irrespective of the diet, 
which is consistent with the results previously reported by our group under standard feeding conditions13. In this 
case, comparable changes have been found under LF- and HF-conditions, reinforcing the idea that both peptides 
exert a direct role on the regulation of PRL release at pituitary level and dismissing the putative indirect action 
through the regulation of other endocrine-metabolic mediators. These results also extend previous data showing 
an opposite role of SST and CORT on the regulation of PRL release and demonstrate that CORT is not a mere 
SST analog in the regulation of endocrine secretions, which have been also observed in the case of non-endocrine 
actions2,9,12–20.
Figure 5. Dynamic insulin tolerance test on male and female, LF- and HF-fed, SST-KO, CORT-KO and 
control mice. Insulin tolerance tests (ITTs) were performed at 17–19 weeks of age (13–15 weeks of diet) under 
ad libitum fed conditions (1 U/kg Novolin, ip) on female and male SST-KO, CORT-KO and control (WT) mice. 
Statistical differences were assessed by two-way ANOVA within genotype and gender followed by Bonferroni 
post-hoc test within each time point [significant differences are indicated by *(WT-LF vs. WT-HF), #(KO-LF vs. 
KO-HF) or &(WT-LF vs. KO-LF)]. Data represent MEM ± SEM of n = 6–12 mice per gender, diet and genotype.
www.nature.com/scientificreports/
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In contrast, despite clear alterations in pituitary axes, lack of SST or CORT did not drastically impacted mice 
growth, body composition or glucose/insulin metabolism, which is in agreement with previous data reported 
in single SST-KO or CORT-KO mice or even in double SST/CORT-KO mice under standard dietary condi-
tions13,25,29,30. Indeed, although HF-feeding demonstrated a significant effect on all the experimental groups in 
terms of increased BW gaining, reduced food intake, elevated adipose tissue weight, altered body composition 
and impaired glucose/insulin metabolism, lack of SST or CORT showed minor effects. Particularly, lack of SST 
did not significantly influence linear growth, body composition or glucose/insulin homeostasis under LF-diet 
feeding, which is consistent with previous studies27,28, but interestingly, augmented the deleterious effects of 
HF-feeding, especially on male mice. Indeed, HF-fed SST-KO male mice exhibited significantly higher body 
weight, with non-significant elevation in the BW of HF-fed SST-KO females compared to controls, which could 
be barely explained by the discrete tendency of the SST-KO animals to exhibit higher food intake. In addition, 
both male and female SST-KO mice presented altered body composition when fed a HF-diet, with increased 
visceral and subcutaneous adipose tissue depots and liver weight; changes that were more pronounced in males. 
Interestingly, male and female SST-KO mice displayed unaltered ITTs under HF-diet, consistent with previous 
results under standard conditions13; however, males presented elevated plasmatic levels of insulin and glucose and 
impaired glucose tolerance, suggesting that female SST-KO mice could be, somehow, protected, at least partially, 
from the deleterious effects of HF-feeding41. These data are also consistent with previous studies under standard 
conditions13 which, altogether, indicate that SST is a key inhibitory regulator of weight gain, body composition 
and whole body glucose homeostasis under conditions of normal/high, but not low, calorie intake.
In contrast to SST-KO mice, lack of endogenous CORT seems to be more important under LF-feeding condi-
tions than in diet-induced obesity conditions. Indeed, although female CORT-KO exhibited a similar phenotype 
than control mice under LF-diet, male CORT-KO mice displayed impaired ITT and elevated fasting glucose 
levels, consistent with previously reports13. These data reinforce the idea that CORT-KO mice are insulin resist-
ant but glucose tolerant in conditions of low/moderate calorie intake, which could be associated to a particular 
pattern and/or magnitude of GH release in CORT-KO mice that could modify the hepatic glucose production in 
response to hyperglycemia or to concomitant changes in other regulatory systems such as glucocorticoids42 or 
SST-KO CORT-KO
Females Males Females Males
LFD HFD LFD HFD LFD HFD LFD HFD
Body weight gain ↑ = = ↑ = = = =
Food intake = = = = = = = =
Body weight (sacrifice) = = = ↑ = = = =
Visceral fat weight = = ↑ ↑ = = = =
Subcutaneous fat weight = ↑ = ↑ = = = =
Plasma Leptin levels = = = = = = = =
Liver weight ↑ ↑ ↑ = = = = =
Pancreas weight = = = = = = = =
Plasma GH levels ↑ ↑ = = = = ↑ =
Pituitary GH expression = = = = = = = =
Hypothalamic Ghrelin 
expression = = = = = = = =
Hypothalamic GHRH 
expression = = = = = = = =
Liver MUP3 expression = ↓ ↓ ↓ = = = =
Liver PRL-R expression ↑ = ↑ ↑ = = = =
Plasma IGF-I levels = = ↓ ↓ = = = =
Liver IGF-I exxpressiion = = = = = = = =
Plasma PRL levels ↑ ↑ = = ↓ ↓
Pituitary PRL expression = ↑ = = = = = =
GTT = = = ↓ = = = =
AUC GTT = = = = = = = =
ITT = = = = = = ↓ =
AUC ITT = = = = = = = =
Fasting Glucose levels = = ↑ ↑ = = = =
Fed Glucose levels = = = = = = = =
Fed Insulin levels = = = ↑ = = = =
Table 1.  Summary of the endocrine-metabolic parameters determined in female and male SST-KO, 
CORT-KO and control (WT) mice fed a LF- of a HF-diet. ↑ and ↓ indicate significant changes compared to 
sex and diet matched wild-type controls.  indicate non-significant tendencies compared to sex and diet 
matched wild-type controls.
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ghrelin24,25,43–45 as previously hypothesized13. However, lack of CORT was not essential to maintain linear growth, 
body composition or appropriate glucose/insulin metabolism under high calories intake as HF-fed CORT-KO 
males and females exhibited similar metabolic alterations than HF-fed controls.
Interestingly, we have recently reported that CORT is essential to protect the mammary gland against the 
chemical-induced tumorigenesis and that this action is diet-independent, while the role of SST seems to be more 
restricted to HF-conditions33, which suggests a tight interplay between the SST/CORT axis and the metabolic 
(lean/obese) status in the control of a wide variety of physiological and pathological functions that may strongly 
depend on the particular end-point analyzed and, therefore, highlight the necessity of taking into consideration 
this interplay when analyzing the role of these pivotal hormones. Altogether, the data presented herein demon-
strate a gender- and diet-dependent role of endogenous SST and CORT on the control of key endocrine and met-
abolic parameters such as pituitary hormones secretion (i.e. GH and PRL), body growth and body composition 
or glucose/insulin homeostasis and, add further evidence to the contention that SST and CORT are not two mere 
endocrine functional siblings. Indeed, in this case, SST seems to be more important than CORT in controlling the 
parameters mentioned above and, therefore, suggests a clear dissociation of SST/CORT physiological functions. 
Therefore, additional efforts should be needed to unveil the specific and distinctive mechanism of action of SST 
and CORT, inasmuch as this novel information could pave the way towards the identification and/or development 
of useful tools in the management of endocrine-metabolic pathologies.
Material and Methods
Animal studies. All experimental procedures were approved by the IACUC of the University of Cordoba 
and were performed in accordance with the appropriate guidelines and regulations. C57Bl6/J SST-KO (kindly 
provided by Dr. Ute Hochgeschwender) and CORT-KO mice were bred in-house and maintained under standard 
conditions (12 h light/dark cycle; lights on at 07:00 h; 22–24C), with free access to tap water and food [standard 
rodent chow (SAFE-diets, Barcelona, Spain)]. The development and validation of Sst− /− and Cort− /− mice as 
well as the methods to determine the genotypes by conventional PCR of tail-snip DNA have been previously repo
rted13,27,30,33,46. Specifically, male and female C57Bl/6 J wild-type (Sst + /+ and Cort + /+ ; Controls, WT), SST-KO 
(Sst − /− ) and CORT-KO (Cort − /− ) littermate mice were generated from heterozygous breeding pairs (Sst+ /− 
or Cort + /− mice, respectively). Littermates were singled-housed at 4 weeks of age and randomly divided in two 
groups fed a low-fat (LF; Research Diets, Gentofte, Denmark; D12450B; 10% Kcal fat, 70% Kcal carbohydrates, 
20% Kcal proteins) or a micronutrient-matched high-fat diet (HF; Research Diets; D12492; 60% Kcal fat, 20% 
Kcal carbohydrates, 20% Kcal proteins) for 14–16 weeks (n = 6–12 mice per gender, diet and genotype). Before 
experimental manipulation and/or euthanasia, mice were handled daily for two weeks to acclimate them to per-
sonnel and handling methods. All (male or female) mice were euthanized the same day (between 08:00–10:00 h) 
by decapitation without anesthesia and trunk blood was collected, mixed with EDTA and Miniprotease inhibitor 
(Roche, Barcelona, Spain), and kept in ice until further centrifugation to obtain plasma. All females were eutha-
nized under random cycling conditions. Tissues were immediately excised, weighted and snap-frozen in liquid 
nitrogen. In particular, visceral and subcutaneous fat depots were directly dissected from the abdominal cavity 
and the abdominal subcutaneous region, respectively. Plasma and tissues were stored at − 80C until posterior 
analysis. Analysis of SST and CORT levels at the hypothalamus by qPCR (see below) further confirmed the gen-
otypes (Supplemental Fig. 1).
In vivo evaluation of metabolic status. Every week, body weight (BW) was monitored to screen the 
effectiveness of HF-diet to induce an obese phenotype. Food intake was estimated at 15–17 weeks of age (11–13 
weeks of diet) by daily weighting food provided and withdrawn during 7 consecutive days. Glucose tolerance tests 
(GTTs) were performed at 16–18 weeks of age (12–14 weeks of diet) after an overnight fast (2 g/kg glucose, ip) 
and insulin tolerance tests (ITTs) were performed at 17–19 weeks of age (13–15 weeks of diet) under ad libitum 
fed conditions (1 U/kg Novolin, ip), beginning between 0800 h–0900 h. Blood was collected at t0, for insulin and 
glucose levels determination.
Circulating hormones measurement. Blood glucose was assessed by glucometer (Accu-Chek system; 
Roche Diagnostics, Barcelona, Spain). Commercial ELISA kits validated for the in vitro quantitative measurement 
of hormones in mouse serum or plasma were used to assess circulating GH, insulin (Millipore), leptin, IGF-I 
(Immunodiagnostic Systems, Bolton, UK) and prolactin (CalBiotech, Spring Valley, CA) following manufactur-
er’s instructions.
Quantitative real-time PCR (qPCR). Total RNA from mouse tissues (hypothalamus, pituitary and liver) 
was extracted, reverse transcribed, and amplified by quantitative real-time PCR using specific sets of primers, 
as previously described13,30,47,48. To control for variations in the amount of RNA used and the efficiency of RT 
reaction, mRNA copy number of each transcript was adjusted by a normalization factor (NF) obtained from 
the expression of three housekeeping genes [Beta-actin (ACTB), cyclophilin A and/or Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT)], using the Genorm 3.3 application49, where the expression of these house-
keeping genes was not significantly altered between the experimental groups. Details of primers used in qPCR 
are provided in Suppl. Table 1.
Statistical analysis. Samples from all groups were processed at the same time. Male and female results were 
analyzed independently and the effect of genotype, the diet and/or the time was assessed by two-way ANOVA, 
followed by Bonferroni test for multiple comparisons. All values are expressed as mean ± SEM. p < 0.05 was 
considered significant. All statistics analyses were performed using the GraphPad Prism 5.0 software (GraphPad 
Software Inc., La Jolla, CA, USA).
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